SCHEMBL3521029

SCHEMBL3521029

CCOC(=O)CNC(=O)c1c(O)c(-c2cc(F)cc(Br)c2)cc2nccnc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.34
CASP1 P29466 1/20 0.34
HPGD P15428 3/20 0.34
ALDH1A1 P00352 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KDM4E B2RXH2 3/20 0.33
CYP17A1 P05093 2/20 0.33
CYP21A2 P08686 2/20 0.33
CYP11B1 P15538 2/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 2/20 0.33
GAA P10253 2/20 0.32
MLYCD O95822 1/20 0.32
TP53 P04637 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521397 0.98 EGLN3 (0.46) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3520915 0.86 EGLN3 (0.63) EGLN3
SCHEMBL3524111 0.83 EGLN3 (0.46) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3521107 0.83 EGLN3 (0.44) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3521075 0.80 EGLN3 (0.52) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3519693 0.79 EGLN3 (0.54) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3522363 0.79 EGLN3 (0.69) EGLN3
SCHEMBL3528917 0.78 EGLN3 (0.48) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3520286 0.78 EGLN3 (0.57) EGLN3SMN1; SMN2CASP1HPGDALDH1A1
SCHEMBL3528513 0.77 EGLN3 (0.46) EGLN3SMN1; SMN2CASP1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885SMN1; SMN2 3777/4885CASP1 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.